Tuberculosis (TB) is a serious global public health challenge that results in significant
morbidity and mortality worldwide. TB is caused by infection with the bacilli Mycobacterium …

While most studies of T lymphocytes have focused on T cells reactive to complexes of
peptide and major histocompatibility complex (MHC) proteins, many other types of T cells do …

Most studies on the immunotherapeutic potential of T cells have focused on CD8 and CD4 T
cells that recognize peptide antigens (Ag) presented by polymorphic major histocompatibility …

There are 9 million cases of active tuberculosis reported annually; however, an estimated
one-third of the world's population is infected with Mycobacterium tuberculosis and remains …

Mucosal-associated invariant T cells (MAIT cells) express a semi-invariant T cell receptor
(TCR) α-chain, TRAV1-2–TRAJ33, and are activated by vitamin B metabolites bound by the …

Immune responses to Mycobacterium tuberculosis are only partially effective; they drive the
bacteria into a latent state, but rarely eliminate them. Unfortunately, the latent state of M …

Clinical trials of vaccines against Mycobacterium tuberculosis are well under way and
results are starting to come in. Some of these results are not so encouraging, as exemplified …

Over the past 15 years, investigators have shown that T lymphocytes can recognize not only
peptides in the context of MHC class I and class II molecules but also foreign and self-lipids …

One third of the global population is estimated to be latently infected with Mycobacterium
tuberculosis. We performed a phase I randomized controlled trial of isoniazid preventive …

The human body frequently encounters harmful bacterial pathogens and employs immune
defense mechanisms designed to counteract such pathogenic assault. In the adaptive …